NCT06861894

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 164 (estimated)
• Sponsor: Zhigang Li · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing management following neoadjuvant therapy with adebrelimab (anti-PD-L1) concurrent with chemoradiotherapy. The primary endpoint is 2-year overall survival rate in this watch-and-wait cohort.

Conditions

• Esophageal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Adebrelimab and nab-paclitaxel and carboplatin	Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy
RADIATION	Radiation	concurrent chemoradiotherapy
PROCEDURE	standard oesophagectomy	standard oesophagectomy
OTHER	active surveillance	active surveillance

Timeline

• Start date: 2025-07-01
• Primary completion: 2027-03-01
• Completion: 2029-03-01
• First posted: 2025-03-06
• Last updated: 2025-05-15

Locations

1 site across 1 country: China